Reactivation of mutant p53 by a dietary-related compound phenethyl isothiocyanate inhibits tumor growth

M Aggarwal1, R Saxena2, E Sinclair1

  • 1Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA.

Insights

Phenethyl isothiocyanate (PEITC), a compound from cruciferous vegetables, reactivates mutant p53 (a tumor suppressor) in cancer cells. This dietary compound shows promise for cancer therapy by restoring normal p53 function and inhibiting tumor growth.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Nutritional Biochemistry

Background:

  • Mutations in the p53 tumor-suppressor gene are common in human cancers, leading to loss of its tumor-suppressive functions.
  • Missense mutations, including contact and structural types, disable wild-type (WT) p53 activities.
  • Small molecules capable of restoring WT p53 function offer potential cancer therapeutic strategies.

Purpose of the Study:

  • To investigate the potential of phenethyl isothiocyanate (PEITC), a dietary compound, to reactivate mutant p53.
  • To explore the anticancer mechanisms of PEITC, particularly its effects on p53(R175) mutants.

Main Methods:

  • In vitro and in vivo assays to assess PEITC's effect on p53 mutant reactivation and cancer cell growth.
  • Mechanistic studies involving apoptosis induction, cell cycle analysis, and target gene activation.
  • Evaluation of PEITC's impact on proteasomal and autophagic degradation pathways.
  • In vivo tumor growth inhibition in a xenograft mouse model.

Main Results:

  • PEITC reactivated p53 mutant, including the common p53(R175) hotspot mutation, restoring WT p53 conformation and transactivation functions.
  • PEITC induced p53-dependent apoptosis, cell cycle delay, and ATM/CHK2 phosphorylation.
  • PEITC's anticancer effects were dependent on the cellular redox state and enhanced degradation of the reactivated p53 mutant.
  • Dietary PEITC supplementation inhibited tumor growth in vivo.

Conclusions:

  • PEITC reactivates mutant p53, demonstrating a novel mechanism for a dietary compound.
  • PEITC exhibits anticancer activity by restoring p53 tumor-suppressive functions and promoting mutant p53 degradation.
  • These findings suggest PEITC's potential for cancer prevention and therapy.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
10.3K
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
3.3K